ERBB2 and cancer: Encouragingly, our research denotes that an anti-ECD I nanobody-based antibody, A9B5-Fc, had superior HER2 internalization activity and further mediated effective anti-proliferation effect, suggesting the theranostic potential for HER2-positive cancer treatment.